Compare EVO & GAIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVO | GAIN |
|---|---|---|
| Founded | 1993 | 2005 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 568.6M | 651.5M |
| IPO Year | 2007 | 2005 |
| Metric | EVO | GAIN |
|---|---|---|
| Price | $1.66 | $15.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $4.17 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 153.5K | 153.5K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 6.13% |
| EPS Growth | N/A | ★ 20.63 |
| EPS | N/A | ★ 0.76 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.83 |
| Revenue Next Year | $20.51 | $6.16 |
| P/E Ratio | ★ N/A | $20.71 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $13.14 |
| 52 Week High | $4.27 | $17.14 |
| Indicator | EVO | GAIN |
|---|---|---|
| Relative Strength Index (RSI) | 46.64 | 39.16 |
| Support Level | $1.50 | $13.64 |
| Resistance Level | $1.97 | $16.94 |
| Average True Range (ATR) | 0.05 | 0.26 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 76.00 | 17.61 |
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S., to achieve and grow current income by investing in debt securities of established businesses, and to provide stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.